Heather Bresch, CEO of Mylan.

Adam Jeffery | CNBC

Drugmaker Mylan missed Wall Street estimates for quarterly revenue on Tuesday, hurt by restructuring at its Morgantown plant in West Virginia and a stronger dollar, sending its shares down 4.5%.

Revenue from its North America business fell 6% to $922.9 million and missed estimates of $952.43 million, largely due to increased competition.

Total revenue fell 7% to $2.50 billion and missed estimates of $2.69 billion, according to IBES data from Refinitiv.

The company reported a net loss of $25 million, or 5 cents per share, in the first quarter ended March 31, compared with profit of $87.1 million, or 17 cents per share, a year earlier.

Excluding items, the company earned 82 cents per share and beat expectations of 79 cents per share.

Products You May Like

Articles You May Like

Why we love to binge on stressful shows like ‘Chernobyl’ and ‘Black Mirror’
Trump-Xi meeting at the G-20 could impact the Fed’s next move, economist says
Airbnb goes high-end with listings in castles and private islands
Investor Karen Firestone: What the pros do when they are underperforming (other than panic)
Here are the top 10 places to own a home and pay less in taxes

Leave a Reply

Your email address will not be published. Required fields are marked *